{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:29:49Z","timestamp":1775561389584,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2007,11,9]]},"DOI":"10.1007\/s00296-007-0422-6","type":"journal-article","created":{"date-parts":[[2007,7,31]],"date-time":"2007-07-31T03:16:44Z","timestamp":1185851804000},"page":"103-111","source":"Crossref","is-referenced-by-count":21,"title":["Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol"],"prefix":"10.1007","volume":"28","author":[{"given":"J. D.","family":"Ringe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schacht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"issue":"Suppl 2","key":"422_CR1","first-page":"22","volume":"7","author":"JD Ringe","year":"2000","unstructured":"Ringe JD (2000) Perspectives of combined treatment strategies in osteoporosis. J Menopause 7(Suppl 2):22\u201323","journal-title":"J Menopause"},{"key":"422_CR2","first-page":"3013","volume":"84","author":"P Alexandersen","year":"1999","unstructured":"Alexandersen P, Riis BJ, Christiansen C (1999) Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocriol Metab 84:3013\u20133020","journal-title":"J Clin Endocriol Metab"},{"key":"422_CR3","first-page":"16","volume":"2","author":"M Gambacciani","year":"1995","unstructured":"Gambacciani M, Spinetti A, Cappagli B, Ciaponi M, Gallo R, Rovati LC, Genazzani AR (1995) Effects of low-dose monofluorophosphate and transdermal oestradiol on postmenopausal vertebral bone loss. Eur Menopause J 2:16\u201320","journal-title":"Eur Menopause J"},{"key":"422_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00296-002-0193-z","volume":"22","author":"JD Ringe","year":"2002","unstructured":"Ringe JD, Setnikar I (2002) Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study. Rheumatol Int 22:27\u201332","journal-title":"Rheumatol Int"},{"key":"422_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/ard.56.6.357","volume":"56","author":"WF Lems","year":"1997","unstructured":"Lems WF, Jacobs JWG, Bijlsma WJ, van Veen GJM, Houben HHML, Haanen HCM, Gerrits MI, van Rijn HJM (1997) Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticoid induced osteoporosis? Ann Rheumatol Dis 56:357\u2013363","journal-title":"Ann Rheumatol Dis"},{"key":"422_CR6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00223-001-1050-x","volume":"69","author":"JD Ringe","year":"2001","unstructured":"Ringe JD, Rovati L (2001) Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252\u2013255","journal-title":"Calcif Tissue Int"},{"key":"422_CR7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s00198-003-1397-0","volume":"14","author":"N Morabito","year":"2003","unstructured":"Morabito N, Gaudio A, Lasco A, Vergara C, Tallarida F, Crisafulli G, Trifiletti A, Cincotta M, Pizzoleo MA, Frisina N (2003) Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 14:500\u2013506","journal-title":"Osteoporos Int"},{"key":"422_CR8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00296-004-0570-x","volume":"25","author":"JD Ringe","year":"2005","unstructured":"Ringe JD, Dorst A, Faber H, Kipshoven C, Rovati LC, Setnikar I (2005) Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study. Rheumatol Int 25:296\u2013300","journal-title":"Rheumatol Int"},{"key":"422_CR9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00198-003-1432-1","volume":"14","author":"JY Reginster","year":"2003","unstructured":"Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Gl\u00fcer CC, M\u00fchlenbacher D, Quail D, Schmitt H, Nickelsen T (2003) Effect of raloxifene combined with monofluoro-phosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 14:741\u2013749","journal-title":"Osteoporos Int"},{"key":"422_CR10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/8756-3282(95)00113-R","volume":"16","author":"PD Delmas","year":"1995","unstructured":"Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH (1995) The anabolic effect of human PTH (1\u201334) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronat. Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603\u2013610","journal-title":"Bone"},{"key":"422_CR11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxseri ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215","journal-title":"N Engl J Med"},{"key":"422_CR12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00044011-199815030-00008","volume":"14","author":"B Frediani","year":"1998","unstructured":"Frediani B, Allegri A, Bisohno S, Marcolongo R (1998) Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 14:235\u2013244","journal-title":"Clin Drug Invest"},{"key":"422_CR13","volume-title":"Alfacalcidol in prevention and treatment of all major forms of osteoporosis and renal osteopathy","author":"JD Ringe","year":"2006","unstructured":"Ringe JD (2006) Alfacalcidol in prevention and treatment of all major forms of osteoporosis and renal osteopathy. Georg Thieme, Stuttgart"},{"key":"422_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90682-2","volume":"93","author":"MJ McKenna","year":"1992","unstructured":"McKenna MJ (1992) Differences in vitamin D status between countries in young adults and the elderly. Am J Med 93:69\u201377","journal-title":"Am J Med"},{"key":"422_CR15","first-page":"1129","volume":"81","author":"MC Chapuy","year":"1996","unstructured":"Chapuy MC, Schott AM, Garnero P, Hans D, Delmas P, Meunier PJ (1996) Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Metab 81:1129\u20131133","journal-title":"J Clin Endocrinol Metab"},{"key":"422_CR16","first-page":"25","volume-title":"Osteoporotic fractures in the elderly","author":"P Burckhardt","year":"1996","unstructured":"Burckhardt P, Krieg MA, Gerber S, Burnand B, Thi\u00e8baud D (1996) Vitamin D: metabolism and specific role in the elderly. In: Ringe JD, Meunier PJ (eds) Osteoporotic fractures in the elderly. Thieme, Stuttgart pp 25\u201336"},{"key":"422_CR17","first-page":"13","volume":"5","author":"E Krexner","year":"1996","unstructured":"Krexner E, Resch H, Pietschmann P, Bernecker P, Woloscuk W, Vukovich T, Geyer G, Willvonseder R (1996) Vitamin D status in residents of a long-term-care geriatric hospital in Vienna. Osteologie 5:13\u201318","journal-title":"Osteologie"},{"key":"422_CR18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","volume":"327","author":"MC Chapuy","year":"1992","unstructured":"Chapuy MC, Arlot ME, DuBoef F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637\u20131642","journal-title":"N Engl J Med"},{"key":"422_CR19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65\u00a0years of age and older. N Engl J Med 337:670\u2013676","journal-title":"N Engl J Med"},{"key":"422_CR20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-124-4-199602150-00003","volume":"124","author":"P Lips","year":"1996","unstructured":"Lips P, Graafsmans WC, Ooms ME, Bezemer PD, Bouter LM (1996) Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 124:400\u2013406","journal-title":"Ann Intern Med"},{"key":"422_CR21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1210\/er.2001-8002","volume":"23","author":"E Papadimitropoulos","year":"2002","unstructured":"Papadimitropoulos E, Wells G, Shea B (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560\u2013569","journal-title":"Endocr Rev"},{"key":"422_CR22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(05)63013-9","volume":"365","author":"The RECORD Trial group","year":"2005","unstructured":"The RECORD Trial group (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621\u20131628","journal-title":"Lancet"},{"key":"422_CR23","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0140-6736(05)66385-4","volume":"365","author":"P Sambrook","year":"2005","unstructured":"Sambrook P (2005) Vitamin D and fractures: quo vadis ? Lancet 365:1599\u20131600","journal-title":"Lancet"},{"key":"422_CR24","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/bmj.330.7498.1003","volume":"330","author":"J Porthouse","year":"2005","unstructured":"Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, Baverstock M, Birks Y, Dumville J, Francis R, Iglesias C, Puffer S, Sutcliffe A, Watt I, Torgerson DJ (2005) Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 330:1003\u20131006","journal-title":"BMJ"},{"key":"422_CR25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa055218","volume":"354","author":"RD Jackson","year":"2006","unstructured":"Jackson RD, LaCroix AZ, Gass M, Wallace R, Robbins J, Lewis CE, Bassford T, et al (2006) Calcium plus vitamin D supplementation and risk of fractures. N Engl J Med 354:669\u2013683","journal-title":"N Engl J Med"},{"key":"422_CR26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002239900702","volume":"65","author":"KHW Lau","year":"1999","unstructured":"Lau KHW, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295\u2013306","journal-title":"Calcif Tissue Int"},{"key":"422_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-004-0454-0","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Schacht E (2004) Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int 24:189\u2013197","journal-title":"Rheumatol Int"},{"key":"422_CR28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(79)91076-6","volume":"1","author":"SG Papopoulos","year":"1979","unstructured":"Papopoulos SG, Fraher LJ, Sandler LM, Clemens TL, Lewin IG, O\u2019Riordan JLH (1979) 1,25-Dihydroxycholecalciferol in the pathogenesis of hypercalcemia of sarcoidosis. Lancet 1:627\u2013631","journal-title":"Lancet"},{"key":"422_CR29","volume-title":"Osteoporosis and active vitamin D metabolites. The shape of things to come","author":"MA Dambacher","year":"1996","unstructured":"Dambacher MA, Schacht E (1996) Osteoporosis and active vitamin D metabolites. The shape of things to come. EULAR, Basle"},{"key":"422_CR30","first-page":"S8","volume":"15","author":"H Smith","year":"2004","unstructured":"Smith H, Anderson F, Raphael H, Crozier S, Cooper C (2004) Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial. Osteoporos Int 15:S8","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"422_CR31","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/PL00022731","volume":"8","author":"JD Ringe","year":"1998","unstructured":"Ringe JD (1998) Vitamin D deficiency and osteopathies. Osteoporos Int 8(Suppl 1):S35\u2013S39","journal-title":"Osteoporos Int"},{"key":"422_CR32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","volume":"310","author":"NAT Hamdy","year":"1995","unstructured":"Hamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Llins R, Fairey IT (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Brit Med J 310:358\u2013363","journal-title":"Brit Med J"},{"key":"422_CR33","volume-title":"Treatment of metabolic bone disease","author":"M Sch\u00f6mig","year":"2000","unstructured":"Sch\u00f6mig M, Lamichhane B, Ritz E (2000) Renal bone disease. In: Hosking D, Ringe JD (eds) Treatment of metabolic bone disease. Martin Dunitz, London"},{"key":"422_CR34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0169-6009(90)90040-M","volume":"9","author":"E Ogata","year":"1990","unstructured":"Ogata E (1990) Hypoparathyroidism: practice and theoretical background for 1\u03b1-OH-D treatment. Bone Miner 9:229\u2013232","journal-title":"Bone Miner"},{"key":"422_CR35","volume-title":"Treatment of metabolic bone disease","author":"M Davies","year":"2000","unstructured":"Davies M (2000) Treatment of osteomalacia. In: Hosking D, Ringe JD (eds) Treatment of metabolic bone disease. Martin Dunitz, London"},{"key":"422_CR36","first-page":"26","volume":"32","author":"SH Scharla","year":"2005","unstructured":"Scharla SH, Schacht E, Lempert UG (2005) Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J Rheumatol 32:26\u201332","journal-title":"J Rheumatol"},{"key":"422_CR37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1532-5415.2004.52060.x","volume":"52","author":"L Dukas","year":"2004","unstructured":"Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stahelin HB (2004) Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500\u00a0mg daily. J Am Geriatr Soc 52:230\u2013236","journal-title":"J Am Geriatr Soc"},{"key":"422_CR38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jsbmb.2004.03.059","volume":"89\u201390","author":"JC Gallagher","year":"2004","unstructured":"Gallagher JC (2004) The effects of calcitriol on falls and fractures and physical performance test\u2019s. J Steroid Biochem Mol Biol 89\u201390:497\u2013501","journal-title":"J Steroid Biochem Mol Biol"},{"key":"422_CR39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/8756-3282(95)80023-J","volume":"16","author":"F Ichikawa","year":"1995","unstructured":"Ichikawa F, Sato K, Nanjo M, Nishi Y, Shinki T, Takahahi N, Suda T (1995) Mouse primary osteoblasts express vitamin D 25-hydroxylase mRNA and convert 1\u03b1,25-dihydroxyvitamin D3. Bone 16:129\u2013135","journal-title":"Bone"},{"key":"422_CR40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1359\/jbmr.2002.17.4.622","volume":"17","author":"T Shibata","year":"2002","unstructured":"Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masud Y, Hisihiya A, Ishikura N, Higashi S, Uchida Y, Saito M, Ito M, Ogata E, Watanabe K, Ikeda K (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622\u2013629","journal-title":"J Bone Miner Res"},{"key":"422_CR41","first-page":"127","volume":"5","author":"M Runge","year":"2005","unstructured":"Runge M, Schacht E (2005) Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskelet Neuronal Interact 5:127\u2013134","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"422_CR42","doi-asserted-by":"crossref","unstructured":"Ones K, Schacht E, Dukas L, Caglar N (2007) Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years, randomized, multiarm, controlled trial. Int J Epidemiol 4(1)","DOI":"10.5580\/1523"},{"key":"422_CR43","first-page":"S87","volume":"74","author":"E Kataxaki","year":"2004","unstructured":"Kataxaki E, Koulouris G, Marketos G, Fragakis N, Georgiadis AE (2004) Combined treatment of alendronate plus alphacalcidol on bone mass in postmenopausal osteoporosis. Calcif Tissue Int 74:S87\u2013S88","journal-title":"Calcif Tissue Int"},{"key":"422_CR44","first-page":"S253","volume":"40","author":"O Bock","year":"2007","unstructured":"Bock O, Boerst H, Runge M, Armbrecht G, Martus P, Schacht E, Hashimoto J, Felsenberg D (2007) Effects of alfacalcidol and alendronate on bone in previously untreated postmenopausal women with osteopenia or osteoporosis: one year interim subgroup analysis of the alfa study. Bone 40:S253","journal-title":"Bone"},{"key":"422_CR45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.57.6.346","volume":"57","author":"T Masud","year":"1998","unstructured":"Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD (1998) Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 57:346\u2013349","journal-title":"Ann Rheum Dis"},{"key":"422_CR46","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00776-003-0655-5","volume":"8","author":"J Iwamoto","year":"2003","unstructured":"Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M (2003) Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. J Orthop Sci 8:532\u2013537","journal-title":"J Orthop Sci"},{"key":"422_CR47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s007760100060","volume":"6","author":"E Shiota","year":"2001","unstructured":"Shiota E, Tsuchiya K, Yamaoka K, Kawano O (2001) Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alfacalcidol in postmenopausal osteoporosis. J Orthop Sci 6:133\u2013136","journal-title":"J Orthop Sci"},{"key":"422_CR48","volume-title":"Osteoporosis in dialogue. 100 questions\u2013100 answers","author":"JD Ringe","year":"2001","unstructured":"Ringe JD (2001) Osteoporosis in dialogue. 100 questions\u2013100 answers. Thieme, Stuttgart"},{"key":"422_CR49","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1359\/jbmr.2003.18.4.769","volume":"18","author":"EP Paschalis","year":"2003","unstructured":"Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL (2003) Bone mineral and collagen quality in numeri of ovariectomized cynomolgus monkeys given rhPTH(1\u201334) for 18\u00a0months. J Bone Miner Res 18:769\u2013775","journal-title":"J Bone Miner Res"},{"key":"422_CR50","first-page":"37","volume":"10","author":"T Fujita","year":"1992","unstructured":"Fujita T, Fukase M, Shimada T, Yamamoto H (1992) Treatment of established osteoporosis with 1\u03b1-(OH)-vitamin D3 and low dose intermittent elcalcitonin (eel calcitonin derivative). JBBM 10:37\u201340","journal-title":"JBBM"},{"key":"422_CR51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0378-5122(01)00243-2","volume":"40","author":"T Ushiroyama","year":"2001","unstructured":"Ushiroyama T, Ikeda A, Sakai M, Higashiyama T, Ueki M (2001) Effects of combined use of calcitonin and 1\u03b1-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas 40:229\u2013238","journal-title":"Maturitas"},{"key":"422_CR52","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1210\/jcem.86.8.7703","volume":"86","author":"JC Gallagher","year":"2001","unstructured":"Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618\u20133628","journal-title":"J Clin Endocrinol Metab"},{"key":"422_CR53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00198-003-1432-1","volume":"14","author":"JY Reginster","year":"2003","unstructured":"Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Gl\u00fcer CC, M\u00fchlenbacher D, Quail D, Schmitt H, Nickelsen T (2003) Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Osteoporos Int 14:741\u2013749","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"422_CR54","first-page":"S186","volume":"21","author":"I Gorai","year":"2006","unstructured":"Gorai I, Tanaka Y, Iwacki Y (2006) Raloxifene when combined with 1\u03b1(OH)vitamin D more greatly suppresses bone turnover and increases bone density than when used alone in postmenopausal Japanese women with osteoporosis or osteopenia. J Bone Miner Res 21(Suppl 1):S186","journal-title":"J Bone Miner Res"},{"key":"422_CR55","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","volume":"27","author":"JD Ringe","year":"2007","unstructured":"Ringe JD, Farahmand P, Schacht E, Rozenal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-trial). Rheumatol Int 27:425\u2013428","journal-title":"Rheumatol Int"},{"key":"422_CR56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1532-5415.2007.01161.x","volume":"55","author":"A Barone","year":"2007","unstructured":"Barone A, Giusti A, Piolu G, Girasole G, Razzano M, Palummeri E, Bianchi G (2007) Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral response to alendronate in elderly women with osteoporosis: a randomized controlled trial. J Am Geriatr Soc 55:752\u2013757","journal-title":"J Am Geriatr Soc"},{"key":"422_CR57","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E","volume":"42","author":"S Amin","year":"1999","unstructured":"Amin S, LaValley MP, Simms RW, Felson DT (1999) The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42:1740\u20131751","journal-title":"Arthritis Rheum"},{"key":"422_CR58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00198-003-1570-5","volume":"15","author":"F Richy","year":"2004","unstructured":"Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301\u2013310","journal-title":"Osteoporos Int"},{"key":"422_CR59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00223-004-0005-4","volume":"76","author":"F Richy","year":"2005","unstructured":"Richy F, Schacht E, Bruy\u00e8re O, Ethgen O, Gourlay M, Reginster JY (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures. A comparative meta-analysis. Calcif Tissue Int 76:176\u2013186","journal-title":"Calcif Tissue Int"},{"key":"422_CR60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00296-003-0361-9","volume":"24","author":"JD Ringe","year":"2004","unstructured":"Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW (2004) Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 24:63\u201370","journal-title":"Rheumatol Int"},{"key":"422_CR61","first-page":"75","volume":"9","author":"JY Reginster","year":"1999","unstructured":"Reginster JY, Kuntz D, Verdicht W, Wouters M, Guillevin L, Menkes C-J, et al (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Bone 9:75\u201381","journal-title":"Bone"},{"issue":"Suppl 1","key":"422_CR62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s003930070040","volume":"59","author":"P Lakatos","year":"2000","unstructured":"Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, et al (2000) Prevention of corticosteroid-induced osteoporosis by alphacalcidol. Z Rheumatol 59(Suppl 1):48\u201361","journal-title":"Z Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0422-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-007-0422-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0422-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:16:08Z","timestamp":1559027768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-007-0422-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,11,9]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s00296-007-0422-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}